These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38330136)

  • 41. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
    Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
    Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.
    Park JW; Lee JK; Sheu KM; Wang L; Balanis NG; Nguyen K; Smith BA; Cheng C; Tsai BL; Cheng D; Huang J; Kurdistani SK; Graeber TG; Witte ON
    Science; 2018 Oct; 362(6410):91-95. PubMed ID: 30287662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
    Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
    Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
    Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.
    Saito M; Shiraishi K; Goto A; Suzuki H; Kohno T; Kono K
    Jpn J Clin Oncol; 2018 Jul; 48(7):603-608. PubMed ID: 29762727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
    Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
    J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
    Park JW; Lee JK; Phillips JW; Huang P; Cheng D; Huang J; Witte ON
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4482-7. PubMed ID: 27044116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
    Giaccone G; He Y
    Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
    Zhu HE; Yin JY; Chen DX; He S; Chen H
    Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma.
    Fiore M; Trecca P; Perrone G; Amato M; Righi D; Trodella L; D'Angelillo RM; Ramella S
    Tumori; 2019 Dec; 105(6):NP12-NP16. PubMed ID: 30799776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.
    Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
    Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
    Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
    Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
    Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
    Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.